Abivax (ABVX) Return on Capital Employed (2025 - 2026)
Abivax's (ABVX) quarterly Return on Capital Employed came in at 50.43% in Q1 2026, up 16829.0% year-on-year from N/an in Q1 2025, and down 16.64% quarter-over-quarter from 43.23% in Q4 2025.
Abivax (ABVX) Return on Capital Employed (2025 - 2026) Analysis & Trends
Abivax's Return on Capital Employed history runs 2 years deep, the most recent figure standing at 50.43% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 16829.0% year-over-year to 50.43% in Q1 2026; TTM through Mar 2026 was 50.43%, a 16829.0% increase from a year earlier, with the FY2025 full-year figure at 75.83%, up 2524.0% from the prior year.
- Return on Capital Employed retreated to 50.43% in Q1 2026 per ABVX's latest filing, from 43.23% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 43.23% in Q4 2025 and bottomed at 716.91% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Abivax | 9.98 Bn | 9.98 Bn | - | -50.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.43% |
| Dec 31, 2025 | -43.23% |
| Sep 30, 2025 | -67.94% |
| Jun 30, 2025 | -716.91% |
| Mar 31, 2025 | -218.72% |